The company plans to use the funding to accelerate growth and increase production capacity at the company’s New York City-based biotechnology manufacturing facility, according to an Oct. 27 Cresilon news release.
Cresilon began with making hemostatic gel for animals and now has plans to expand into the human health market. The funding round was led by Paulson Investment Co.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
